ESPR
Esperion Therapeutics, Inc.
$3.14
+0.00%
2026-05-08
About Esperion Therapeutics, Inc.
Esperion Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was formerly known as HDL Therapeutics, Inc. and changed its name to Esperion Therapeutics, Inc. in May 2008. The company was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
Key Fundamentals
Forward P/E
12.97
EPS (TTM)
$-0.11
Revenue Growth (YoY)
143.7%
Profit Margin
-5.6%
Beta
0.91
Market Cap
$809.6M
Avg Volume (10D)
31.8M
Recent Breakout Signals
No recent breakout signals detected for ESPR.
Recent Price Range (60 Days)
60D High
$3.69
60D Low
$1.80
Avg Volume
10.1M
Latest Close
$3.14
Get breakout alerts for ESPR
Sign up for Breakout Scanner to receive daily notifications when ESPR triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Esperion Therapeutics, Inc. (ESPR) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors ESPR daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. ESPR operates in the Healthcare sector within the Drug Manufacturers - Specialty & Generic industry. Data is provided for informational purposes only and does not constitute financial advice.